Study started April 2023, Ongoing

ClinicalTrials.gov Identifier: NCT05885932

ClinicalTrials.gov: https://clinicaltrials.gov/ct2/show/NCT05885932?cond=Drug-eluting +Stenting+Versus+Medical+Treatment+Alone+for+Patients+With+Extracranial+Vertebral+Artery+Stenosis&draw=2&rank=1

The drug-eluting stenting versus medical therapy alone for patients with extracranial vertebral artery stenosis (VISTA) trial, is a government-funded, prospective, multicenter, randomized controlled trial. It will recruit patients with 3 months stroke or TIA caused by 70-99% stenosis of extracranial vertebral artery (V1-2 segments). Patients will be randomized (1:1) to best medical treatment alone or medical treatment plus stenting. Primary outcome is a composite of any fatal or non-fatal stroke within 30 days after randomization, or ischemic stroke in the territory of the target artery beyond 30 days to 1 year.  Recruitment is expected to be finished by Sep, 2025. The first stage of the trial is scheduled to complete in 2027.

Keywords:

Extracranial vertebral artery stenosis, Drug-eluting stenting, Best medical treatment, Ischemic stroke.

Relevant article:

●Markus HS, Larsson SC, et al. VIST Investigators. Stenting for symptomatic vertebral artery stenosis: The Vertebral Artery Ischaemia Stenting Trial. Neurology. 2017 Sep 19;89(12):1229-1236. doi: 10.1212/WNL.0000000000004385IF: 9.9 Q1 . Epub 2017 Aug 23. PMID: 28835400; PMCID: PMC5606920.

●Turan TN, Zaidat OO, et al. Stroke Prevention in Symptomatic Large Artery Intracranial Atherosclerosis Practice Advisory: Report of the AAN Guideline Subcommittee. Neurology. 2022 Mar 22;98(12):486-498. doi: 10.1212/WNL.0000000000200030IF: 9.9 Q1 . PMID: 35314513; PMCID: PMC8967328.

●Compter A, et al. VAST investigators. Stenting versus medical treatment in patients with symptomatic vertebral artery stenosis: a randomised open-label phase 2 trial. Lancet Neurol. 2015 Jun;14(6):606-14. doi: 10.1016/S1474-4422(15)00017-4. Epub 2015 Apr 20. PMID: 25908089.